BioSpecifics Files 8K - Director, Officer or Compensation Filing >BSTC
BioSpecifics Files 8K - Director, Officer or Compensation Filing >BSTC
DJ BioSpecifics Files 8K - Director, Officer or Compensation Filing >BSTC
DJ生物鑑定文件8K-董事，官員或薪酬申請>英國科技公司
BioSpecifics Technologies Corp. (BSTC) filed a Form 8K - Director, Officer or Compensation Filing - with the U.S Securities and Exchange Commission on January 07, 2020.
生物科技公司(BioSpecifics Technologies Corp.)於2020年1月7日向美國證券交易委員會提交了一份8K表格--董事高管或薪酬申請。
Appointment of Chief Financial Officer
任命首席財務官
The Board of Directors of the Company (the "Board") approved the appointment of Mr. Patrick C. Hutchison as Chief Financial Officer of the Company, effective as of January 6, 2020 (the "Effective Date").
本公司董事會(“董事會”)批准委任Patrick C.Hutchison先生為本公司首席財務官，自2020年1月6日(“生效日期”)起生效。
Mr. Hutchison, 61, served as the Chief Financial Officer of SwanBio Therapeutics ("SwanBio"), a private gene therapy biotech company, on a part-time basis from April 2019 through December 2019. Before SwanBio, from April 2017 to August 2018, Mr. Hutchison served as the Chief Financial Officer of Innocoll, Inc., a private biotech company. Prior to that, Mr. Hutchison served as the Chief Financial Officer of TetraLogic Pharmaceuticals ("TetraLogic"), a public biotech company, from April 2016 to December 2016 and as TetraLogic's Vice President Finance from January 2014 to April 2016. From 2012 to 2013, Mr. Hutchison was Teleflex, Inc.'s Vice President Corporate Controller and Chief Accounting Officer. Before his time at Teleflex, Inc., from 2001 to 2012, Mr. Hutchison was Vice President Group Controller of Cephalon, Inc., an international biopharmaceutical company. Mr. Hutchison received his B.S. degree in Accounting from the Wharton School of the University of Pennsylvania ("UPenn"); he also earned a B.A. degree in Psychology from UPenn.
Hutchison先生現年61歲，於2019年4月至2019年12月期間兼職擔任私營基因治療生物科技公司SwanBio Treateutics(“SwanBio”)的首席財務官。在加入SwanBio之前，哈奇森於2017年4月至2018年8月擔任私營生物科技公司Innocoll，Inc.的首席財務官。在此之前，Hutchison先生於2016年4月至2016年12月擔任上市生物科技公司TetraLogic PharmPharmticals(“TetraLogic”)的首席財務官，並於2014年1月至2016年4月擔任TetraLogic的財務副總裁。2012年至2013年，Hutchison先生擔任Teleflex，Inc.公司副總裁兼首席會計官。2001年至2012年，Hutchison先生在Teleflex公司任職之前，是國際生物製藥公司Cephalon，Inc.的副總裁集團總監。Hutchison先生擁有賓夕法尼亞大學沃頓商學院(UPenn)會計學學士學位；他還獲得了賓夕法尼亞大學心理學學士學位。
In connection with his appointment as Chief Financial Officer on a part-time basis, the Company entered into a letter agreement with an effective date of January 6, 2020 with Mr. Hutchison (the "Employment Agreement") setting forth the terms of his employment and compensation. Pursuant to the Employment Agreement, Mr. Hutchison's base salary will be $200,000, and he will be eligible for an annual incentive cash bonus with a target amount of 20% of his annual rate of base salary. Mr. Hutchison is also eligible to participate in the employee benefits and insurance programs that are generally provided by the Company to its employees.
關於他被委任為兼職首席財務官，本公司與和記先生訂立了一份生效日期為二零二零年一月六日的函件協議(“僱傭協議”)，列明其僱用及補償條款。根據僱傭協議，Hutchison先生的底薪為200,000美元，他將有資格獲得年度獎勵現金獎金，目標金額為其年基本工資的20%。Hutchison先生還有資格參加公司通常為其員工提供的員工福利和保險計劃。
Pursuant to the Employment Agreement, on the Effective Date, Mr. Hutchison will receive a one-time stock option grant with respect to 10,000 shares of common stock of the Company (the "Option") under the Company's 2019 Omnibus Incentive Compensation Plan (the "Equity Plan"). The Option will have an exercise price equal to the fair market value per share on the date of grant and will vest in equal annual installments over the four-year period following the date of grant, subject to the terms and conditions established by the Board and of the Equity Plan.
根據僱傭協議，於生效日期，和記黃埔先生將根據本公司2019年綜合激勵薪酬計劃(“股權計劃”)，獲授本公司10,000股普通股的一次性購股權(“購股權”)。根據董事會及股權計劃訂立的條款及條件，購股權將於授出日行使相當於每股公平市價的行使價，並於授出日起計四年內按年等額分期付款。
If Mr. Hutchison's employment is terminated by the Company without "Cause" (as defined in the Employment Agreement), Mr. Hutchison will be entitled to receive any earned but unpaid base salary through the date of termination (at the rates then in effect, less standard deductions and withholdings). In addition, in such event, if Mr. Hutchison executes a waiver and general release of claims in the form provided by the Company to Mr. Hutchison, then he will be eligible to receive an aggregate amount equal to
如和記黃埔先生被本公司無故終止聘用(定義見僱傭協議)，和記黃埔先生將有權領取任何已賺取但未支付的基本薪金至終止日期(按當時生效的比率，較低的標準扣減及扣除額)。此外，在這種情況下，如果和記黃埔先生按照公司向和記黃埔提供的格式簽署了一項豁免和全面免除索賠的協議，那麼他將有資格獲得相當於
two months of his then-current base salary (less standard deductions and withholdings) payable in equal installments over the two-month period following the date of his termination. In the event Mr. Hutchison resigns from the Company or the Company terminates his employment at any time for "Cause" or due to death or Disability (as defined in the Employment Agreement), the Company will pay to Mr. Hutchison any earned but unpaid base salary and any unused vacation accrued (if applicable) through the date of such resignation or termination (at rates then in effect, less standard deductions and withholdings).
兩個月當時的基本工資(減去標準扣除和扣繳)，在他被解僱之日後的兩個月期間內平均分期付款。倘若Hutchison先生辭任本公司或本公司於任何時間因“因由”或因死亡或殘疾(定義見僱傭協議)而終止僱用，本公司將向Hutchison先生支付任何已賺取但尚未支付的基本薪金及截至辭職或終止日期為止的任何未用假期(如適用)(按當時有效的較低標準扣減及扣除額計算)。
Termination of Principal Financial Officer
解僱首席財務官
Prior to the Effective Date, Mr. Patrick Caldwell was serving as the Company's interim Principal Financial Officer. On the Effective Date, the Company provided notice to Mr. Caldwell of its intent to terminate Mr. Caldwell's Consulting Agreement, dated April 1, 2019, with such termination effective as of March 31, 2020. Mr. Caldwell will continue to be employed by the Company through March 31, 2020, during which time he will serve as the Company's Principal Accounting Officer and assist in the transition of his responsibilities and duties to Mr. Hutchison.
生效日期前，Patrick Caldwell先生擔任本公司臨時首席財務官。於生效日期，本公司向考德威爾先生發出通知，表示有意於2019年4月1日終止考德威爾先生的諮詢協議，該終止自2020年3月31日起生效。Caldwell先生將繼續受僱於本公司直至2020年3月31日，在此期間，他將擔任本公司的首席會計官，並協助將其職責移交給Hutchison先生。
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/875622/000119312520003123/d861231d8k.htm
這份美國證券交易委員會申報文件的全文可在以下網址查閲：http://www.sec.gov/Archives/edgar/data/875622/000119312520003123/d861231d8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: https://www.sec.gov/Archives/edgar/data/875622/000119312520003123/0001193125-20-003123-index.htm
任何有關美國證券交易委員會備案的展品和相關文件都可以在以下網址獲得：https://www.sec.gov/Archives/edgar/data/875622/000119312520003123/0001193125-20-003123-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
上市公司必須在任何可能對公司財務狀況或股票價值產生重大影響的事件發生後四天內向美國證券交易委員會提交一份當前報告。
(END) Dow Jones Newswires
(完)道瓊通訊社
January 07, 2020 17:16 ET (22:16 GMT)
2020年01月07日東部時間17：16(格林尼治標準時間22：16)
Copyright (c) 2020 Dow Jones & Company, Inc.
版權所有(C)2020道瓊斯公司。
譯文內容由第三人軟體翻譯。
